Revolution Medicines Completes Acquisition of EQRx
November 09, 2023 09:10 ET
|
Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
November 08, 2023 11:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for...
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
November 06, 2023 16:05 ET
|
Revolution Medicines, Inc.
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
November 01, 2023 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
UPDATE - Scipher Medicine Welcomes Sam Davis as General Counsel
September 24, 2021 12:00 ET
|
Scipher Medicine Corporation
WALTHAM, Mass., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of Sam A....
Scipher Medicine Welcomes Sam Davis as General Counsel
September 24, 2021 09:00 ET
|
Scipher Medicine Corporation
WALTHAM, Mass., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of Sam A....